European regulators moved to pull Amgen’s vasculitis drug Tavneos from the market after the European Commission canceled its marketing authorization. The recall orders all batches of Tavneos (avacopan) as regulators align with the higher-level decision. For biotech and pharma, the move underscores how quickly treatment access can change in rare-disease and specialty markets when authorization status shifts. Companies relying on EU commercialization should expect tighter contingency planning for distribution, pharmacovigilance, and labeling transitions.